◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › VTRS

Viatris Inc (VTRS) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Pharmaceuticals · DATA UPDATED 2026-07-18

Viatris Inc (VTRS) operates in the Pharmaceuticals industry and is headquartered in Canonsburg, United States with about 30,000 employees. Its market capitalization is roughly $20 billion. In the fiscal year ended 2025-12-31, VTRS reported $14.3B in revenue and ($3.5B) in net income.

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.

Interactive charts & full statements → Open the VTRS valuation workbench →

VTRS Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$14.6B	$14.3B	$14.7B	$15.4B	$16.3B	$17.9B	$11.9B	$11.5B	$11.4B	$11.9B	$11.1B	$9.4B	$7.7B	$6.9B	$6.8B	$6.1B	$5.5B	$5.1B	$5.1B	$2.9B	$1.6B
Gross Profit	$5.0B	$5.0B	$5.6B	$6.4B	$6.5B	$5.6B	$3.8B	$3.9B	$4.0B	$4.8B	$4.7B	$4.2B	$3.5B	$3.0B	$2.9B	$2.6B	$2.2B	$2.1B	$2.1B	$1.2B	$844M
Gross Margin %	34.4%	35.1%	38.1%	41.7%	40.0%	31.2%	31.8%	33.9%	35.0%	40.2%	42.4%	44.7%	45.7%	44.0%	42.8%	41.8%	40.7%	40.7%	40.3%	40.1%	52.3%
Operating Income (EBIT)	$139M	($2.7B)	$10M	$766M	$1.6B	($34M)	($211M)	$716M	$906M	$1.4B	$699M	$1.5B	$1.4B	$1.1B	$1.1B	$1.0B	$722M	$523M	$298M	$372M	$428M
Operating Margin %	1.0%	-18.6%	0.1%	5.0%	9.9%	-0.2%	-1.8%	6.2%	7.9%	12.1%	6.3%	15.5%	17.5%	16.4%	16.3%	16.4%	13.2%	10.3%	5.8%	12.8%	26.5%
Net Income	($296M)	($3.5B)	($634M)	$55M	$2.1B	($1.3B)	($670M)	$17M	$352M	$696M	$480M	$848M	$929M	$624M	$641M	$537M	$345M	$233M	($196M)	($1.5B)	$217M
Net Margin %	-2.0%	-24.6%	-4.3%	0.4%	12.8%	-7.1%	-5.6%	0.1%	3.1%	5.8%	4.3%	9.0%	12.0%	9.0%	9.4%	8.8%	6.3%	4.6%	-3.8%	-52.2%	13.5%
EBITDA	$2.6B	($395M)	$2.8B	$3.5B	$6.4B	$4.5B	$2.0B	$2.7B	$3.0B	$3.2B	$2.1B	$2.3B	$1.9B	$1.6B	$1.7B	$1.5B	$1.1B	$947M	$735M	($992M)	$683M
Earnings Per Share (EPS)	$-0.26	$-3.00	$-0.53	$0.05	$1.71	$-1.05	$-1.11	$0.03	$0.68	$1.30	$0.92	$1.70	$2.34	$1.58	$1.52	$1.22	$1.05	$0.76	$-0.64	$-5.90	$0.99
Shares Outstanding (M)	1,175M	1,171M	1,193M	1,207M	1,217M	1,209M	601M	516M	516M	537M	520M	497M	398M	394M	420M	439M	329M	307M	304M	257M	219M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VTRS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$3.5B	$3.7B	$3.8B	$3.6B	$3.3B	$3.5B	$3.8B	$3.8B
Gross Profit	$1.2B	$1.1B	$1.4B	$1.3B	$1.2B	$1.2B	$1.5B	$1.4B
Gross Margin %	32.9%	30.6%	36.8%	37.2%	35.7%	34.4%	38.9%	38.1%
Operating Income (EBIT)	($80M)	($266M)	$252M	$233M	($2.9B)	($180M)	$226M	($240M)
Operating Margin %	-2.3%	-7.2%	6.7%	6.5%	-88.6%	-5.1%	6.0%	-6.3%
Net Income	$176M	($340M)	($128M)	($5M)	($3.0B)	($516M)	$95M	($326M)
Net Margin %	5.0%	-9.2%	-3.4%	-0.1%	-93.5%	-14.6%	2.5%	-8.6%
EBITDA	$644M	$543M	$800M	$578M	($2.3B)	$340M	$906M	$540M
Earnings Per Share (EPS)	$0.15	$-0.30	$-0.11	$-0.00	$-2.55	$-0.43	$0.08	$-0.27
Shares Outstanding (M)	1,175M	1,153M	1,165M	1,173M	1,192M	1,193M	1,200M	1,191M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VTRS Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$2.2B	$2.3B	$2.3B	$2.8B	$3.0B	$3.0B	$1.2B	$1.8B	$2.3B	$2.1B	$2.0B	$2.0B	$1.0B	$1.1B	$949M	$720M	$931M	$605M	$384M	$168M	$390M
Capital Expenditures (CapEx)	$459M	$379M	$326M	$474M	$443M	$509M	$681M	$406M	$252M	$276M	$390M	$363M	$325M	$335M	$305M	$280M	$193M	$154M	$165M	$111M	$162M
Free Cash Flow (FCF)	$1.7B	$1.9B	$2.0B	$2.3B	$2.5B	$2.5B	$551M	$1.4B	$2.1B	$1.8B	$1.7B	$1.6B	$690M	$772M	$644M	$441M	$739M	$451M	$219M	$57M	$228M
FCF Margin %	11.7%	13.6%	13.4%	15.1%	15.4%	14.0%	4.6%	12.2%	18.3%	15.0%	15.0%	17.4%	8.9%	11.2%	9.5%	7.2%	13.6%	8.8%	4.3%	2.0%	14.2%
Dividends Paid	$558M	$561M	$575M	$576M	$582M	$399M	$8M	$0M	$399M	—	—	—	—	—	—	—	$139M	$139M	$137M	$30M	$51M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VTRS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$388M	$816M	$745M	$220M	$536M	$483M	$826M	$379M
Capital Expenditures (CapEx)	$40M	$265M	$100M	$54M	$76M	$153M	$85M	$59M
Free Cash Flow (FCF)	$348M	$550M	$645M	$166M	$459M	$329M	$741M	$320M
FCF Margin %	9.9%	14.9%	17.2%	4.6%	14.1%	9.3%	19.8%	8.4%
Dividends Paid	$140M	$138M	$140M	$140M	$143M	$143M	$143M	$146M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VTRS Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$36.8B	$37.2B	$41.5B	$47.7B	$50.0B	$54.8B	$61.6B	$31.3B	$32.7B	$35.8B	$34.7B	$22.3B	$15.8B	$15.3B	$11.9B	$11.6B	$11.5B	$10.8B	$10.4B	$11.4B	$4.3B
Cash & Cash Equivalents	$1.8B	$1.3B	$735M	$992M	$1.3B	$701M	$844M	$476M	$388M	$292M	$999M	$1.2B	$226M	$291M	$350M	$384M	$686M	$428M	$597M	$484M	$1.3B
Total Liabilities	$22.2B	$22.5B	$22.9B	$27.2B	$28.9B	$34.4B	$38.6B	$19.4B	$20.6B	$22.5B	$23.6B	$12.5B	$12.5B	$12.3B	$8.6B	$8.1B	$7.9B	$7.7B	$7.6B	$7.9B	$2.6B
Total Debt (Short + Long-Term)	$14.3B	$14.5B	$14.1B	$18.2B	$19.3B	$23.2B	$25.9B	$12.7B	$13.8B	$14.7B	$15.5B	$1.0B	$2.8B	$456M	$397M	$817M	$167M	$191M	$154M	$550M	$233M
Total Shareholders' Equity	$14.7B	$14.7B	$18.6B	$20.5B	$21.1B	$20.5B	$23.0B	$11.9B	$12.2B	$13.3B	$11.1B	$9.8B	$3.3B	$2.9B	$3.3B	$3.5B	$3.6B	$3.1B	$2.8B	$3.4B	$1.7B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VTRS viewer.

Other Companies in Pharmaceuticals

MRK · Merck & Co. — $324 billion
PFE · Pfizer — $140 billion
BMY · Bristol Myers Squibb — $127 billion
ZTS · Zoetis — $32 billion
LLY · Lilly (Eli) — $1.07 trillion
JNJ · Johnson & Johnson — $635 billion

← VTR All stocks VTS →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.